Cargando…

Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors

SIMPLE SUMMARY: Lung cancer is the leading cause of cancer-related death worldwide. Nonsmall cell lung cancer (NSCLC) accounts for 80–85% of all cases. Immune checkpoint inhibitors (ICIs) have revolutionized the field of oncology by improving survival in cancer patients. However, given their limited...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kudura, Ken, Ritz, Nando, Kutzker, Tim, Hoffmann, Martin H. K., Templeton, Arnoud J., Foerster, Robert, Kreissl, Michael C., Antwi, Kwadwo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776660/ https://www.ncbi.nlm.nih.gov/pubmed/36551581 http://dx.doi.org/10.3390/cancers14246095

Ejemplares similares

Additional Primary Tumors Detected Incidentally on FDG PET/CT at Staging in Patients with First Diagnosis of NSCLC: Frequency, Impact on Patient Management and Survival
por: Kudura, Ken, et al.
Publicado: (2023)

Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition
por: Kudura, Ken, et al.
Publicado: (2023)

An Innovative Non-Linear Prediction Model for Clinical Benefit in Women with Newly Diagnosed Breast Cancer Using Baseline FDG-PET/CT and Clinical Data
por: Kudura, Ken, et al.
Publicado: (2023)

Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2021)

Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers 2021, 13, 3830
por: Kudura, Ken, et al.
Publicado: (2022)

Hypermetabolic Ipsilateral Supraclavicular and Axillary Lymphadenopathy: Optimal Time Point for Performing an (18)F-FDG PET/CT after COVID-19 Vaccination
por: Antwi, Kwadwo, et al.
Publicado: (2022)

Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2021)

Sex-Related Differences in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition
por: Kudura, Ken, et al.
Publicado: (2022)

Inflammatory Blood Parameters as Biomarkers for Response to Immune Checkpoint Inhibition in Metastatic Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Advanced NSCLC: [(18)F]FDG PET/CT as a Troubleshooter in Treatment Response
por: Ferrari, Cristina, et al.
Publicado: (2021)

Hematogenous muscular metastasis of NSCLC in FDG-PET/CT
por: Satoh, Hiroaki, et al.
Publicado: (2015)

On the Added Value of Baseline FDG-PET in Malignant Lymphoma
por: Quarles van Ufford, Henriette, et al.
Publicado: (2009)

Tumor glycolytic profiling through (18)F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC
por: Silva, Saulo Brito, et al.
Publicado: (2022)

Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab
por: Seban, Romain-David, et al.
Publicado: (2020)

Can Dynamic Whole-Body FDG PET Imaging Differentiate between Malignant and Inflammatory Lesions?
por: Skawran, Stephan, et al.
Publicado: (2022)

[F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients
por: Nappi, Antonio, et al.
Publicado: (2015)

Comparison between FDG-PET/CT and bone scan in bone metastasis from NSCLC
por: Tamura, Tomohiro, et al.
Publicado: (2014)

FDG-PET and colon cancer
por: Miles, Ken
Publicado: (2015)

Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy
por: Watanabe, Shiro, et al.
Publicado: (2019)

Automated quantification of baseline imaging PET metrics on FDG PET/CT images of pediatric Hodgkin lymphoma patients
por: Weisman, Amy J., et al.
Publicado: (2020)

Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT
por: Park, Sohyun, et al.
Publicado: (2020)

Clinical value of baseline (18)F-FDG PET/CT in soft tissue sarcomas
por: Reyes Marlés, Rafael Hernando, et al.
Publicado: (2021)

Whole-body parametric [(18)F]-FDG PET/CT improves interpretation of a distant lesion as venous embolus in a lung cancer patient
por: Messerli, Michael, et al.
Publicado: (2021)

Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma
por: Ferdinandus, Justin, et al.
Publicado: (2022)

Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [(18)F]FDG PET/CT
por: Liberini, Virginia, et al.
Publicado: (2021)

Early and Complete Response of Bone Metastases, Documented by FDG-PET/CT Scan, in a Patient With NSCLC
por: Rossi, David, et al.
Publicado: (2012)

Convolutional Neural Networks Promising in Lung Cancer T-Parameter Assessment on Baseline FDG-PET/CT
por: Kirienko, Margarita, et al.
Publicado: (2018)

Prognostic Values of Baseline (18)F-FDG PET/CT in Patients with Peripheral T-Cell Lymphoma
por: Zhou, Yeye, et al.
Publicado: (2020)

Diagnostic value of baseline (18)FDG PET/CT skeletal textural features in follicular lymphoma
por: Faudemer, Julie, et al.
Publicado: (2021)

The impact of baseline (18)F-FDG PET-CT on the management and outcome of patients with gastric cancer
por: Foley, Kieran G, et al.
Publicado: (2022)

Monitoring scanner calibration using the image-derived arterial blood SUV in whole-body FDG-PET
por: Maus, Jens, et al.
Publicado: (2018)

(18)F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI data
por: Besson, Florent L., et al.
Publicado: (2020)

Recent and Current Advances in FDG-PET Imaging within the Field of Clinical Oncology in NSCLC: A Review of the Literature
por: Kaseda, Kaoru
Publicado: (2020)

Impact of (18)F-FDG PET/CT, CT and EBUS/TBNA on preoperative mediastinal nodal staging of NSCLC
por: Al-Ibraheem, Akram, et al.
Publicado: (2021)

Differences between TNM classification and 2-[(18)F]FDG PET parameters of primary tumor in NSCLC patients
por: Cegla, Paulina, et al.
Publicado: (2021)

The Incremental Prognostic Value of Baseline (18)F-FDG PET/CT Imaging in Angioimmunoblastic T-Cell Lymphoma
por: Wang, Hui, et al.
Publicado: (2020)

When SUV Matters: FDG PET/CT at Baseline Correlates with Survival in Soft Tissue and Ewing Sarcoma
por: Hack, Ruben I., et al.
Publicado: (2021)

Effects of cigarette smoking on metabolic activity of lung cancer on baseline (18)F-FDG PET/CT
por: Jiang, Maoqing, et al.
Publicado: (2022)

Impact of EBUS-TBNA in addition to [(18)F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC
por: Guberina, Maja, et al.
Publicado: (2021)

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
por: Huang, Richard S P, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gelbeoreck00kd0h2a6lesak53